Compare CAR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAR | GRFS |
|---|---|---|
| Founded | 1946 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.2B |
| IPO Year | 1998 | 2008 |
| Metric | CAR | GRFS |
|---|---|---|
| Price | $138.61 | $7.85 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $136.57 | $10.15 |
| AVG Volume (30 Days) | 271.2K | ★ 350.3K |
| Earning Date | 04-29-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | ★ 50.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,652,000,000.00 | N/A |
| Revenue This Year | $2.10 | $4.49 |
| Revenue Next Year | $1.81 | $6.42 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $85.96 | $6.96 |
| 52 Week High | $847.70 | $10.23 |
| Indicator | CAR | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 50.65 |
| Support Level | $133.56 | $7.66 |
| Resistance Level | $149.85 | $8.36 |
| Average True Range (ATR) | 5.57 | 0.18 |
| MACD | 0.51 | -0.03 |
| Stochastic Oscillator | 30.47 | 27.74 |
Avis Budget Group Inc is a provider of mobility solutions through its three brands Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. Its brands offer a range of options, from car and truck rental to car sharing. The company operates in two reportable business segments: Americas - (i) vehicle rental operations in North America, South America, Central America and the Caribbean, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly. International - consisting of (i) vehicle rental operations in Europe, the Middle East, Africa, Asia and Australasia, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.